Filamin A in triple negative breast cancer

被引:1
|
作者
Giovannelli, Pia [1 ]
Di Donato, Marzia [1 ]
Licitra, Fabrizio [1 ]
Sabbatino, Emilia [1 ]
Tutino, Viviana [1 ]
Castoria, Gabriella [1 ]
Migliaccio, Antimo [1 ]
机构
[1] Univ Campania L Vanvitelli, Dept Precis Med, Via L De Crecchio 7, I-80138 Naples, Italy
关键词
Triple negative breast cancer; Filamin A; TNBC marker; Androgen receptor; ACTIN-BINDING PROTEIN; PERIVENTRICULAR HETEROTOPIA; ANDROGEN RECEPTOR; CROSS-LINKING; EXPRESSION; INVASION; SURVIVAL; FLNA; PHOSPHORYLATION; MIGRATION;
D O I
10.1016/j.steroids.2024.109380
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Triple-negative breast cancer is a rare but highly heterogeneous breast cancer subtype with a limited choice of specific treatments. Chemotherapy remains the only efficient treatment, but its side effects and the development of resistance consolidate the urgent need to discover new targets. In TNBC, filamin A expression correlates to grade and TNM stage. Accordingly, this protein could constitute a new target for this BC subtype. Even if most of the data indicates its direct involvement in cancer progression, some contrasting results underline the need to deepen the studies. To elucidate a possible function of this protein as a TNBC marker, we summarized the main characteristic of filamin A and its involvement in physiological and pathological processes such as cancer. Lastly, we scrutinized its actions in triple-negative breast cancer and highlighted the need to increase the number of studies useful to better clarify the role of this versatile protein as a marker and target in TNBC, alone or in "collaboration" with other proteins with a relevant role in this BC subgroup.
引用
收藏
页数:8
相关论文
共 50 条
  • [2] Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway
    Zhao, Pengxin
    Ma, Weiyuan
    Hu, Zhigang
    Zang, Leilei
    Tian, Zhisheng
    Zhang, Kaili
    TUMOR BIOLOGY, 2016, 37 (04) : 5107 - 5115
  • [3] Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer
    Yan, Shunchao
    Dey, Parama
    Ziegler, Yvonne
    Jiao, Xin
    Kim, Sung Hoon
    Katzenellenbogen, John A.
    Katzenellenbogen, Benita S.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (02) : 281 - 292
  • [4] Triple negative breast cancer in Asia: An insider's view
    Wang, Chao
    Kar, Shreya
    Lai, Xianning
    Cai, Wanpei
    Arfuso, Frank
    Sethi, Gautam
    Lobie, Peter E.
    Goh, Boon C.
    Lim, Lina H. K.
    Hartman, Mikael
    Chan, Ching W.
    Lee, Soo C.
    Tan, Sing H.
    Kumar, Alan P.
    CANCER TREATMENT REVIEWS, 2018, 62 : 29 - 38
  • [5] Triple-Negative Breast Cancer: An Unmet Medical Need
    Hudis, Clifford A.
    Gianni, Luca
    ONCOLOGIST, 2011, 16 : 1 - 11
  • [6] Targeting the androgen receptor in triple-negative breast cancer
    Gucalp, Ayca
    Traina, Tiffany A.
    CURRENT PROBLEMS IN CANCER, 2016, 40 (2-4) : 141 - 150
  • [7] Triple-Negative Breast Cancer Role of the Androgen Receptor
    Gucalp, Ayca
    Traina, Tiffany A.
    CANCER JOURNAL, 2010, 16 (01) : 62 - 65
  • [8] Targeting triple-negative breast cancer: A clinical perspective
    Popovic, Lazar S.
    Matovina-Brko, Gorana
    Popovic, Maja
    Punie, Kevin
    Cvetanovic, Ana
    Lambertini, Matteo
    ONCOLOGY RESEARCH, 2023, 31 (03) : 221 - 238
  • [9] Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer
    Li, Xiaoxian
    Yang, Jing
    Peng, Limin
    Sahin, Aysegul A.
    Huo, Lei
    Ward, Kevin C.
    O'Regan, Ruth
    Torres, Mylin A.
    Meisel, Jane L.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (02) : 279 - 287
  • [10] Triple-negative breast cancer and the potential for targeted therapy
    Jhan, Jing-Ru
    Andrechek, Eran R.
    PHARMACOGENOMICS, 2017, 18 (17) : 1595 - 1609